Published in Cell Cycle on December 07, 2005
Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A (2009) 1.38
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Carcinog (2008) 1.38
Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases. J Toxicol Environ Health B Crit Rev (2011) 0.98
Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors. J Cancer Res Clin Oncol (2008) 0.96
Hippo/YAP pathway for targeted therapy. Transl Lung Cancer Res (2014) 0.87
Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing. BMC Med Genet (2009) 0.81
Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma. Am J Pathol (2011) 0.81
Inhibition of RUNX2 transcriptional activity blocks the proliferation, migration and invasion of epithelial ovarian carcinoma cells. PLoS One (2013) 0.81
Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities. Carcinogenesis (2007) 0.77
A murine model for the development of melanocytic nevi and their progression to melanoma. Mol Carcinog (2015) 0.77
P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas. Eur Arch Otorhinolaryngol (2014) 0.75
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology (2008) 5.28
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev (2010) 3.77
Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. Genes Dev (2005) 3.59
Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology (2014) 3.31
Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology (2007) 3.18
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun (2013) 3.06
Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet (2002) 2.85
Release of metal particles from needles used for transbronchial needle aspiration. Chest (2010) 2.70
Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology (2014) 2.68
NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev (2003) 2.55
A critical role for peptidoglycan N-deacetylation in Listeria evasion from the host innate immune system. Proc Natl Acad Sci U S A (2007) 2.46
Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell (2010) 2.38
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology (2009) 2.20
Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci U S A (2003) 2.16
Role for DNA repair factor XRCC4 in immunoglobulin class switch recombination. J Exp Med (2007) 2.05
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J (2004) 1.85
Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology (2013) 1.85
MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest (2012) 1.83
Colorectal cancers in a new mouse model of familial adenomatous polyposis: influence of genetic and environmental modifiers. Lab Invest (2004) 1.82
Hemorrhagic complications in patients with advanced hematological malignancies followed at home: an Italian experience. Leuk Lymphoma (2009) 1.80
Genetics of hepatobiliary carcinogenesis. Semin Liver Dis (2011) 1.79
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A (2013) 1.72
Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res (2007) 1.71
Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet (2007) 1.68
Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol (2007) 1.65
FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res (2003) 1.64
Transfusions at home in patients with myelodysplastic syndromes. Leuk Res (2012) 1.59
Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology (2008) 1.58
Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology (2005) 1.52
Tissue-specific conditional CCM2 knockout mice establish the essential role of endothelial CCM2 in angiogenesis: implications for human cerebral cavernous malformations. Dis Model Mech (2009) 1.49
Oxidative stress and proinflammatory effects of carbon black and titanium dioxide nanoparticles: role of particle surface area and internalized amount. Toxicology (2009) 1.46
Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab (2004) 1.46
Pleural plaques and the risk of pleural mesothelioma. J Natl Cancer Inst (2013) 1.46
Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene (2002) 1.45
Bioluminescence imaging of live infected salmonids reveals that the fin bases are the major portal of entry for Novirhabdovirus. J Virol (2006) 1.45
The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest (2009) 1.44
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev (2002) 1.43
Anticoagulant and Anti-thrombotic Treatments in the Management of Hematological Malignancies in a Home Care Program. Indian J Palliat Care (2011) 1.42
CARD15/NOD2 is required for Peyer's patches homeostasis in mice. PLoS One (2007) 1.41
Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep (2005) 1.41
Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med (2009) 1.41
Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology (2013) 1.36
HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem (2007) 1.36
Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis (2011) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Subtype classification of hepatocellular adenoma. Dig Surg (2010) 1.33
Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res (2004) 1.31
CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer (2011) 1.26
Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol (2012) 1.25
GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. J Hepatol (2011) 1.25
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A (2011) 1.24
Making quality of life assessment a dashboard for patient management. Support Care Cancer (2014) 1.23
Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation. Gastroenterology (2003) 1.22
Germline hepatocyte nuclear factor 1alpha and 1beta mutations in renal cell carcinomas. Hum Mol Genet (2005) 1.22
Cre-mediated germline mosaicism: a new transgenic mouse for the selective removal of residual markers from tri-lox conditional alleles. Nucleic Acids Res (2003) 1.21
Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis (2010) 1.21
Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol (2007) 1.21
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy. Cancer Res (2010) 1.18
Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int (2008) 1.17
Loss of hepatocyte nuclear factor 1alpha function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology (2010) 1.15
Pain and anxiety associated with bone marrow aspiration and biopsy: a prospective study on 152 Italian patients with hematological malignancies. Ann Hematol (2011) 1.15
Spectrum of HNF1A somatic mutations in hepatocellular adenoma differs from that in patients with MODY3 and suggests genotoxic damage. Diabetes (2010) 1.13
The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol (2007) 1.13
Hepatocellular adenoma: what is new in 2008. Hepatol Int (2008) 1.12
WNT signaling increases proliferation and impairs differentiation of stem cells in the developing cerebellum. Development (2012) 1.12
Colonic epithelial expression of ErbB2 is required for postnatal maintenance of the enteric nervous system. Neuron (2003) 1.12
Impairment of NO-dependent relaxation in intralobar pulmonary arteries: comparison of urban particulate matter and manufactured nanoparticles. Environ Health Perspect (2008) 1.10
Mesothelioma: Do asbestos and carbon nanotubes pose the same health risk? Part Fibre Toxicol (2009) 1.10
Magnetic cell sorting for enriching Schwann cells from adult mouse peripheral nerves. J Neurosci Methods (2003) 1.10
Home care management of patients affected by hematologic malignancies: a review. Haematologica (2006) 1.10
Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology (2007) 1.08
The HOX gene network in hepatocellular carcinoma. Int J Cancer (2011) 1.07
Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis (2004) 1.07
The beta-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. J Hepatol (2008) 1.06
Disability and physical rehabilitation in patients with advanced hematological malignancies followed in a home care program. Support Care Cancer (2009) 1.05
Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol (2012) 1.05
Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res (2010) 1.04
Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol (2004) 1.04
STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica (2013) 1.04
Cernunnos deficiency reduces thymocyte life span and alters the T cell repertoire in mice and humans. Mol Cell Biol (2012) 1.04
A novel alpha(v)beta (3)-blocking disintegrin containing the RGD motive, DisBa-01, inhibits bFGF-induced angiogenesis and melanoma metastasis. Clin Exp Metastasis (2007) 1.02
Characterization of the axon initial segment (AIS) of motor neurons and identification of a para-AIS and a juxtapara-AIS, organized by protein 4.1B. BMC Biol (2011) 1.02
A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst (2010) 1.02
Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res (2010) 1.01
The neurofibromatosis 2 protein, merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol Cell Biol (2008) 1.01
Merlin isoform 2 in neurofibromatosis type 2-associated polyneuropathy. Nat Neurosci (2013) 1.01